Paper Details

  1. Home
  2. Paper Details

Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer: results of a Japan Clinical Oncology Group Study (JCOG9401).

Author: AogiKenjiro, FukudaHaruhiko, FukutomiTakashi, InoueKenichi, IwataHiroji, KinoshitaTakayuki, MatsuiAkira, ShibataTaro, ShienTadahiko, TakahashiMasato

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This randomized trial found that adding doxorubicin (A) and cyclophosphamide (C) to tamoxifen (TAM) (ACT) was not highly effective for estrogen receptor positive (ER+), node-positive postmenopausal breast cancer (PMBC). However, adjuvant ACT therapy was considered to be effective for ER-, node-positive PMBC.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Cancer subtype has recently become an increasingly important consideration when deciding the treatment strategy for breast cancer. For the estrogen receptor positive (ER+) subtype, the efficacy of adjuvant endocrine therapy is definitive, but that of adjuvant chemotherapy is controversia...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s10147-013-0657-z

データ提供：米国国立医学図書館（NLM）

Tamoxifen vs. Tamoxifen Plus Chemotherapy: A Complex Equation for Breast Cancer Treatment

The treatment landscape for [breast cancer] is becoming increasingly complex as researchers strive to personalize therapy based on the specific characteristics of the disease. This study explores the effectiveness of adding [doxorubicin] and [cyclophosphamide] to [tamoxifen] as adjuvant therapy for [node-positive postmenopausal breast cancer]. The authors conducted a [randomized trial] involving [129 patients], evaluating the impact of this combination therapy on overall survival and relapse-free survival.

A Tale of Two Subtypes: Chemotherapy's Impact on Breast Cancer Survival Varies

The results of the study, based on [129 patients], indicate that adding [doxorubicin] and [cyclophosphamide] to [tamoxifen] improved relapse-free survival, but the effect on overall survival was less clear. Interestingly, the study observed a significant benefit from combination therapy in patients with [estrogen receptor-negative] breast cancer, but this benefit was less pronounced in patients with [estrogen receptor-positive] breast cancer. This suggests that the effectiveness of combination therapy may depend on the specific subtype of breast cancer.

Navigating the Complexities of Breast Cancer Treatment: A Personalized Approach

This study emphasizes the need for a personalized approach to breast cancer treatment, taking into account the specific characteristics of the tumor. While the study found that adding chemotherapy to tamoxifen might benefit some patients, especially those with ER-negative tumors, it is essential to discuss individual risks and benefits with your healthcare provider. Further research is necessary to understand the optimal treatment strategies for different breast cancer subtypes.

Dr. Camel's Conclusion

Like a skilled navigator charting a course through a vast, shifting desert, the treatment of breast cancer demands a flexible and personalized approach. This study provides valuable insights into the potential benefits and limitations of combination therapy, highlighting the importance of considering individual tumor characteristics. The quest for optimal breast cancer treatment continues, fueled by ongoing research and a commitment to personalized care.

Date :
  1. Date Completed 2015-08-31
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24395447

DOI: Digital Object Identifier

10.1007/s10147-013-0657-z

Related Literature

Article Analysis
・Effective treatment of breast cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.